LEIDEN, Netherlands – September 19, 2025 – AVIGI today announces a strategic decision to prioritise the development of its lead asset, VL166, in the field of kidney disease, while evolving its oncology program to maximize the exploration of the compound's broad pan-cancer potential.
Oncology Program
The development of VL166 in oncology will continue to advance and is being evaluated for a public-private setting. This collaborative approach strategically leverages the Netherlands' excellent and highly integrated oncology infrastructure, providing access to premier research institutions and sophisticated clinical trial networks. This capital-efficient pathway allows AVIGI and partners to thoroughly explore the full pan-cancer potential of VL166. It provides a unique opportunity to investigate its impact across a diverse range of solid tumors and therapeutic combinations, ensuring no stone is left unturned in the fight against cancer.
The Strategic Prioritisation of Kidney Disease
This strategic focus allows AVIGI to concentrate its internal resources and expertise on Kidney Disease, a landscape with enormous unmet medical need where VL166’s highly targeted and selective mechanism of action is exceptionally well-suited. AVIGI is uniquely positioned to succeed in this area, guided by a driven leadership team and a world-class scientific advisory team that possesses a deep, foundational understanding of drug development and kidney disease.
This strategy, a dedicated internal focus on Kidney Disease and a collaborative, expansive approach in oncology positions AVIGI to unlock the full value of VL166 and deliver maximum impact for both patients and stakeholders.
As a tribute to the kidney community we've created a little easter egg that reveals itself when you press our logo below.